Abstract
Objective: Ovarian cancer often presents with advanced-stage disease; however, despite surgery and chemotherapy, recurrence remains inevitable and prognosis poor. Advances in alternative targets including programmed cell death-1 (PD-1) inhibition show promise; however, clinical trials show modest response rates. Ovarian cancer is known to be radiosensitive, but use of total abdominal radiation is not utilized because of high abdominopelvic toxicity. Conventional radiotherapy is delivered at a dose rate of 3–4 Gy/minute, while our ultra-rapid FLASH radiotherapy system uses a linear accelerator to deliver dose rates of 200 Gy/second.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call